聖元環保(300867.SZ):在建年產40000噸化學藥品(食品)原料牛磺酸項目正常有序推進中,預計今年下半年投產
格隆匯5月28日丨聖元環保(300867.SZ)在投資者互動平臺表示,公司目前在建年產40000噸化學藥品(食品)原料牛磺酸項目正常有序推進中,預計今年下半年投產。本項目建設立足高標準高起點,配套行業先進的生產工藝和設備,項目建設標準及質量體系嚴格按照中國GMP、美國cGMP要求進行註冊及認證,並與工程項目設計、建設同步展開,出口資質申請等相關工作也在同步推進中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.